Horizon Therapeutics

Horizon Therapeutics (Dublin, Ireland). Acquired by Amgen (2023) for $27.8B. Tepezza (teprotumumab, thyroid eye disease). Krystexxa (pegloticase). Rare disease and autoimmune franchise.